Insider information pursuant to Article 17 MAR
Berlin, 04.02.2021 - Würzburg based PENTIXAPHARM GmbH, an associate of Eckert & Ziegler AG (ISIN DE0005659700), has received confirmation from the European Medicines Agency (EMA) that its lead candidate PENTIXAFOR may be tested directly in a phase III clinical study. The agency said that there are "sufficient safety data available to initiate a phase III trial" for the Gallium-68 labelled radiodiagnostic which detects CXCR4-positiv solid tumors and CXCR4-positive hematological malignancies.
Contact: |
Information and Explanation of the Issuer to this News:
Details about PENTIXAFOR and the content of the EMA advice will be provided in the next days in a separate PENTIXAPHARM press release.